FDA told Nutritional Sales and Customer Service that its Synedrex supplement is adulterated because it contains three ingredients never notified to FDA as new dietary ingredients.
What happened
FDA's Center for Food Safety and Applied Nutrition reviewed the label of Synedrex, a product the firm sells as a dietary supplement, and found it declares octopamine, hordenine and higenamine as dietary ingredients. FDA said it has no information that these ingredients were marketed in the United States before October 15, 1994, or were present in the food supply unaltered, and it has received no new dietary ingredient notifications for them. FDA added that even with a notification, hordenine and higenamine lack evidence showing they would reasonably be expected to be safe.
What FDA found
The product contains octopamine, hordenine and higenamine, which FDA treats as new dietary ingredients because they were not marketed in the United States before October 15, 1994.
Section 413(d) of the FD&C Act [21 U.S.C. § 350b(d)]The company never filed the required premarket safety notification with FDA at least 75 days before selling the product.
Section 413(a)(2) of the FD&C Act [21 U.S.C. § 350b(a)(2)] and 21 CFR 190.6Because the notification was missing, the supplement is adulterated (legally unfit to sell).
Sections 402(f) and 413(a) of the FD&C Act [21 U.S.C. §§ 342(f) and 350b(a)]There is no evidence that hordenine or higenamine is safe when used as a dietary ingredient, so a notification would not have fixed those two.
Section 402(f)(1)(B) of the FD&C Act [21 U.S.C. § 342(f)(1)(B)]Shipping an adulterated supplement across state lines is prohibited.
Sections 301(a) and (v) of the FD&C Act [21 U.S.C. § 331(a) and (v)]
What FDA wants
FDA asks the company to write back within fifteen working days describing the specific steps taken to fix the violations and prevent them from happening again, with supporting documents. If corrective actions cannot be finished in that time, the company must explain why and say when they will be done.
Who should pay attention
- brands selling stimulant or pre-workout style supplements
- distributors and retailers carrying Synedrex
- contract manufacturers asked to produce blends with hordenine, higenamine or octopamine
This is a summary. Read the original letter on fda.gov.